Alnylam drug wins FDA approval for progressive heart disease
Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce cardiovascular-related death and hospitalizations. This indication was widely expected among investors and is similar to the indications given for competing therapies.
Although officially banned for human consumption by the FDA, alkyl nitrites — commonly known as poppers — have been sold ...
At the Metro Drug Coalition in Knoxville, they see addiction walk through the door every day. According to MDC’s Karen ...
The inspection comes after a ProPublica investigation revealed that drugs made at the Glenmark Pharmaceuticals plant ...
Telix Pharmaceuticals reported that the U.S. Food and Drug Administration approved its agent indicated for prostate cancer ...
Drug compounders are moving to block the FDA’s decision that Novo Nordisk A/S’s weight loss drug is no longer in shortage, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback